Understanding Trop-2 in advanced prostate cancer to find better treatments
Molecular regulation and expression of Trop-2 in advanced prostate cancer: Identifying optimal therapeutic niches
This project looks for new ways to treat advanced prostate cancer by understanding a specific protein called Trop-2.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project ID | NIH-11120973 on NIH RePORTER |
What this research studies
For men with advanced prostate cancer that has become resistant to standard treatments, finding new options is crucial. This project explores the role of a protein called Trop-2 in these aggressive cancers. By learning how Trop-2 works and is expressed, we hope to uncover new weaknesses in cancer cells. This understanding could lead to more effective, targeted therapies for patients who currently have limited choices.
Who could benefit from this research
Good fit: This research is most relevant to men living with metastatic castrate-resistant prostate cancer (mCRPC) who are seeking new treatment options.
Not a fit: Patients whose prostate cancer is still responding well to existing treatments or who do not have advanced, resistant disease may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to the development of new, more effective treatments for men with advanced prostate cancer that no longer responds to current therapies.
How similar studies have performed: While current treatments for advanced prostate cancer have improved, there is a critical need for new agents to overcome resistance, suggesting this approach explores novel therapeutic targets.
Where this research is happening
Madison, United States
- University of Wisconsin-Madison — Madison, United States (Active)
Researchers
- Principal investigator: Lang, Joshua — University of Wisconsin-Madison
- Study coordinator: Lang, Joshua
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.